MSD (known as Merck & Co., Inc. in the US and Canada) and Orion Corporation announced the mutual exercise of an option to convert their co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208), an investigational CYP11A1 inhibitor, into an exclusive global…
Sure, here’s a rewritten version of the article: Today, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for their Omicron JN.1-adapted monovalent COVID-19 vaccine…
Merck known as MSD outside the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously recommended CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years and…
Merck Announces Positive EU CHMP Recommendation for WINREVAIR™ (Sotatercept) in Treating Pulmonary Arterial Hypertension (PAH) Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of…
Cayuga Biotech introduced groundbreaking preclinical findings today on its innovative polyphosphate (polyP)-based therapy aimed at combating life-threatening hemorrhage. The study revealed that the polyP-SNP (silica nanoparticle) complex accelerates thrombin production 12 times faster than conventional methods under both standard and…
PQE Group, a prominent consultancy in the Life Science sector, has announced the launch of its new Regulated Artificial Intelligence & Data Analytics division. This development follows the integration of AI-based tools within the industrial sector, marking a significant milestone…
Takeda has announced that the European Commission (EC) has approved FRUZAQLA (fruquintinib) as a monotherapy for adult patients with metastatic colorectal cancer (mCRC) who have previously been treated with standard therapies. These therapies include fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF…
Sanofi is set to present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), occurring from June 22-26, 2024, in Bangkok, Thailand. Key presentations on ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN…
Eli Lilly and Company (NYSE: LLY) has released detailed results from the SURMOUNT-OSA phase 3 clinical trials, which evaluated tirzepatide injections (10 mg or 15 mg) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without…
Sanofi and Biovac, based in Cape Town, South Africa, have announced a significant partnership aimed at local manufacturing of inactivated polio vaccines (IPV) across Africa. This collaboration marks a milestone as Biovac becomes the first African producer of IPV on…
Takeda Releases Phase 3 Topline Results for Soticlestat (TAK-935) in Dravet Syndrome and Lennox-Gastaut Syndrome OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TSE:4502/NYSE The SKYLINE trial (TAK-935-3001) was a multicenter, randomized, double-blind Phase 3 study examining soticlestat (TAK-935) alongside standard care…
UMC Utrecht has enrolled its first patient for a new study to identify biomarkers of Amyotrophic Lateral Sclerosis (ALS). The observational investigator-initiated study is led by Professor Dr. Leonard van den Berg and supported by VectorY Therapeutics. VectorY Therapeutics is…